06:37:55 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaMERK Equities
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo.


2022-02-15 Bokslutskommuniké 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-09-08 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-14 Ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2021-01-04 Extra Bolagsstämma 2021
2020-12-14 Kvartalsrapport 2020-Q3
2020-09-30 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-30 Kvartalsrapport 2020-Q1
2020-03-31 Bokslutskommuniké 2019
2019-12-31 Kvartalsrapport 2019-Q3
2019-12-20 Extra Bolagsstämma 2019
2019-09-30 Kvartalsrapport 2019-Q2
2019-06-30 Kvartalsrapport 2019-Q1
2019-06-27 Årsstämma 2019
2019-06-03 Ordinarie utdelning SOFTX 0.00 NOK
2019-03-31 Bokslutskommuniké 2018
2018-12-31 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2018-07-02 Split SOFTX 1:50
2018-06-07 Kvartalsrapport 2018-Q1
2020-12-16 09:35:02
In accordance with feedback from the Danish Medicines Agency we have performed
additional safety studies for SIS in a minipig inhalation model, resembling the
human respiratory tract. This study confirmed that mild changes to the
respiratory epithelium when exposed with higher concentrations of SIS have been
documented to be transient and fully reversible," says DVM Elin Jørgensen from
University of Copenhagen (in charge of animal studies).

SoftOx Inhalation Solution (SIS) is an inhalation solution where the hypothesis
is that it should be able to treat all types of respiratory tract infections.
This could potentially be a paradigm shift in the treatment of all types of
respiratory infections.

"Safety-wise, these results are of outmost importance to SoftOx, as it provides
excellent grounds for pursuing safety testing in humans as planned in Q2 2021,"
says Medical Director at SoftOx, Glenn Gundersen.

"This is excellent news and support our aim for SIS to become a well-tolerated
and effective treatment for COVID-19 patients and potentially other respiratory
infections," says Professor in Microbiology and Primary Investigator Thomas
Bjarnsholt*, University of Copenhagen and Rigshospitalet, Denmark.

*Professor Bjarnsholt is one of the inventors of the SoftOx technology, and he
is a member of the SoftOx Solutions AS advisory board. He owns options (20 000)
to acquire shares in the company, and he is being paid for his work for SoftOx
Solutions AS.

Oslo, 16 December 2020

Geir Almås, CEO of SoftOx Solutions AS
Email: geir.almaas@soft-ox.com
Mobile: +47 977 59 071

About SoftOx Solutions AS SoftOx Solutions AS (SoftOx, listed
on the Oslo Stock Exchange Euronext Growth) is a Norwegian MedTech company based
in Oslo with the aim of helping to combat major threats to human health, namely
the emergence of antimicrobial resistance (AMR), biofilm infections in chronic
wounds and the spread of viruses. For more information on SoftOx, visit